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ABSTRACT	  New	  series	  of	  heterocycles	  containing	  1,3,4-­‐oxadiazole	  and	  pyrazole-­‐3-­‐one	  moiety	  have	  been	  synthesized	  and	  evaluated	   in	  vitro	  against	  Staphylococus	  aureus	  NCCS	  2079,	   Bacillus	   cereus	   NCCS	   2106,	   Escherichia	   coli	   NCCS	   2065,	   Pseudomanas	  
aeruginosa	   NCCS	   2200,	  Aspergillus	  niger	   NCCS	   1196	   and	  Candida	  albicans	   NCCS	  2106.	   The	   compounds	   demonstrated	   moderate	   antimicrobial	   activity	   against	  selected	  fungal	  and	  bacterial	  strains.	  
Keywords:	  Synthesis;	  1,3,4-­‐Oxadiazoles;	  Pyrazole-­‐3-­‐ones;	  Antimicrobial	  activity.	  
RESUMEN	  
Nuevos	  compuestos	  que	  contienen	  núcleos	  1,3,4-­‐oxadiazol	  y	  pirazol-­‐3-­‐ona.	  Sintesis	  y	  
actividad	  antimicrobiana	  "in	  vitro"	  Nuevas	   series	   de	   compuestos	   heterocíclicos	   que	   contienen	   1,3,4-­‐oxadiazol	   y	  pyrazol-­‐3-­‐ona	   han	   sido	   sintetizadas	   y	   evaluadas	   in-­‐vitro	   contra	   Staphylococus	  
aureus	   NCCS	   2079,	   	   Bacillus	   cereus	   NCCS	   2106,	   Escherichia	   coli	   NCCS	   2065,	  
Pseudomanas	   aeruginosa	   NCCS	   2200,	   Aspergillus	   niger	   NCCS	   1196	   y	   Candida	  
albicans	   NCCS	   2106.	   Los	   compuestos	   demostraron	   actividad	   antimicrobiana	  moderada	  contra	  estirpes	  fúngicas	  y	  bacterianas	  seleccionadas.	  
Palabras	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  Actividad	  antimicrobiana.	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1.	  INTRODUCTION	  Heterocycles	  bearing	  nitrogen,	  oxygen	  and	  sulphur	  atoms	  in	  their	  structure	  have	   received	   remarkable	   attention	   because	   of	   their	   biological	   and	  pharmacological	   applications	   [1-­‐3].	   Among	   the	  wide	   variety	   of	   heterocycles	   that	  were	  explored	   for	  developing	  pharmaceutically	   important	  molecules,	  compounds	  containing	   1,3,4-­‐oxadiazole	   nucleus	   [4-­‐7]	   and	   pyrazole	   nucleus	   [8-­‐13]	   constitute	  the	   important	   class	   of	   compounds	   exhibiting	   diverse	   and	   extensive	   spectrum	   of	  biological	   activities.	   This	   scenario	   led	   us	   to	   synthesize	   the	   novel	   compounds	   VII	  and	   IX	   containing	   1,3,4-­‐oxadiazole	   and	   pyrazole	   nuclei	   and	   evaluate	   their	  antibacterial	  and	  antifungal	  activities.	  
2.	  MATERIALS	  AND	  METHODS	  All	  chemicals	  used	  were	  analytical	  grade	  obtained	  from	  Merck	  India	  Limited,	  India.	   All	   the	   glass	  ware	   used	  were	   of	   borosilicate	   grade.	   The	   standard	  bacterial	  and	  fungal	  stains	  were	  procured	  from	  National	  Centre	  for	  Cell	  Science,	  Pune,	  India.	  UV-­‐Visible	  spectrophotometer	  manufactured	  by	  Shimadzu	  Corporation,	  Japan	  was	  used	   for	   absorption	   measurements.	   The	   IR	   spectra	   were	   recorded	   on	   a	   Perkin-­‐Elmer	  983	   IR	   spectrometer.	  The	   1H-­‐NMR	  spectra	  were	   recorded	  on	  a	  Bruker	  AC	  300F	   (200	  MHz)	  NMR	   spectrometer	   using	  DMSO	   –	   d6	   as	   solvent	   and	  TMS	   as	   an	  internal	   standard.	  Mass	   spectra	   of	   the	   compounds	  were	   recorded	   on	   a	   Jeol	   JMS-­‐D300	  mass	  spectrometer	  operating	  at	  70	  eV.	  	  	  	  
2.1.	  General	  Synthetic	  Procedures	  	  The	   novel	   compounds	   were	   synthesized	   by	   specified	   procedures	   and	   the	  critical	   intermediate	   compounds	   were	   characterized	   by	   elemental	   analysis	   and	  spectral	  data.	  
2.1.1.	  Synthesis	  of	  {4-­‐[3-­‐Methyl-­‐5-­‐oxo-­‐4-­‐(4|-­‐substituted	  phenyl	  hydrazono)-­‐4,5-­‐
dihydro-­‐pyrazol-­‐1-­‐yl]-­‐phenoxy}-­‐acetic	  acid	  hydrazide	  (V).	  
a.	  	  Synthesis	  of	  substituted	  phenyl	  diazoniam	  chloride	  (I)	  The	   required	   primary	   amine	  was	   dissolved	   in	   a	   suitable	   volume	   of	  water	  containing	   2.5–3.0	   equivalents	   of	   hydrochloric	   acid	   (or	   sulphuric	   acid).	   The	  solution	  was	  cooled	  to	  0	  oC.	  To	  the	  crystals	  of	  amine	  hydrochloride	  (or	  sulphate)	  so	  obtained,	  an	  aqueous	  solution	  of	  sodium	  nitrite	  was	  added	  portion	  wise.	  	  An	  excess	  of	  acid	  was	  necessary	   to	  stabilize	   the	  diazonium	  chloride.	  Similar	  procedure	  was	  adopted	  for	  the	  preparation	  of	  other	  substituted	  phenyl	  diazonium	  chlorides.	  
b.	  Synthesis	  of	  substituted	  phenyl	  diazonium	  ethyl	  acetoacetic	  ester	  (II)	  To	  an	   ice-­‐cold	   solution	  of	  mixture	  of	   sodium	  acetate	   (1.0	   g)	   in	  100	  mL	  of	  aqueous	   alcohol	   and	   ethyl	   acetoacetate	   (0.1	   mol)	   in	   50	   mL	   of	   ethanol,	   the	  corresponding	  diazonium	  chloride	  was	  added	   till	   yellow	  crystals	  were	   separated	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out.	  	  These	  crystals	  were	  filtered,	  washed	  with	  water	  and	  dried.	  
c.	   Synthesis	   of	   3-­‐methyl-­‐4-­‐(substituted	   phenyl	   hydrazono)-­‐pyrazoline-­‐5-­‐one	  
(III)	   3-­‐methyl-­‐4-­‐(4|-­‐substituted	   phenyl	   hydrazono)-­‐pyrozoline-­‐5-­‐one	   (III)	   was	  synthesized	   by	   thecondensation	   of	   4-­‐substituted	   phenyl	   hydrazono	   acetoacetic	  ester	   (II)	   and	   hydrazine	   in	   the	   presence	   of	   required	   amounts	   of	  dimethylformamide.	  The	  mixture	  was	  subjected	  to	  microwave	  irradiation	  at	  150W	  intermittently	   at	   30	   sec	   intervals	   for	   2	   minutes.	   	   After	   complete	   conversion	   as	  indicated	   by	   TLC,	   the	   reaction	  mixture	  was	   cooled	   and	  washed	  with	   cold	  water.	  	  The	  precipitated	  III	  was	  filtered	  recrystallized	  from	  ethanol.	  	  	  	  	  
d.Synthesis	   of	   {4-­‐[3-­‐Methyl-­‐5-­‐oxo-­‐4-­‐(substituted	   phenyl	   hydrazono)-­‐4,5-­‐
dihydro-­‐pyrazol-­‐1-­‐yl]-­‐phenoxy-­‐	  acetic	  acid	  ethyl	  ester	  (IV)	  A	   mixture	   of	   III,	   anhydrous	   K2CO3	   and	   DMF	   was	   stirred	   at	   room	  temperature	   for	   8	   hours.	   	   The	   reaction	  mixture	  was	  diluted	  with	   ice	   cold	  water.	  The	  separated	  solid	  was	  filtered	  and	  recrystallized	  from	  ethanol.	  	  
e.	  Synthesis	  of	  {4-­‐[3-­‐Methyl-­‐5-­‐oxo-­‐4-­‐(4|-­‐aryl-­‐hydrazono)-­‐4,5-­‐dihydro-­‐pyrazol-­‐1-­‐
yl]-­‐phenoxy}-­‐acetic	  acid	  hydrazides	  (V)	  A	   mixture	   of	   IV	   and	   hydrazine	   hydrate	   in	   ethanol	   was	   refluxed	   for	   five	  hours.	   The	   reaction	  mixture	  was	   cooled	   to	   room	   temperature	   and	   poured	   in	   ice	  cold	  water	  with	  continuous	  stirring.	  The	  separated	  solid	  was	  filtered,	  washed	  with	  water	   and	   recrystallized	   from	   ethanol.	   Other	   members	   of	   the	   series	   Vwere	  prepared	  on	  the	  same	  lines.	  The	  reaction	  scheme	  is	  depicted	  in	  Scheme	  1.	  
2.1.2.	  Synthesis	  of	  2-­‐(4-­‐acetyl-­‐	  -­‐5,5-­‐disubstituted	  4,5-­‐dihydro-­‐[1,3,4]oxadiazole-­‐
2-­‐yl(methyloxyphenyl)-­‐5-­‐methyl-­‐4(aryl	  hydrazono)-­‐	  -­‐pyrazol-­‐3-­‐ones	  (VII)	  
a.	   Synthesis	   of	   {4-­‐[3-­‐	   methyl-­‐	   5-­‐	   oxo-­‐	   4-­‐(4|-­‐phenyl	   hydrazono)-­‐	   4,5-­‐dihydro-­‐
pyrazol-­‐1-­‐yl]-­‐phenoxy}-­‐acetic	  acid	  (1-­‐phenyl-­‐ethylidene)-­‐hydrazide	  (VI)	  A	  mixture	   of	   V	   (0.01	  mol)	   in	   hot	  methanol	   (25	  mL),	   acetophenone	   (0.01	  mol)	  and	  a	  drop	  of	  glacial	  acetic	  acid	  were	  refluxed	  for	  3	  hours.	  The	  solid	  separated	  was	  filtered,	  washed	  with	  cold	  methanol	  and	  recrystallized	  from	  methanol	  to	  give	  
VIa.	  Compounds	  VI	  b-­‐h	  were	  synthesized	  on	  similar	  lines.	  
b.	   Synthesis	   of	   2-­‐(4-­‐acetyl-­‐5,5-­‐disubstituted	   4,5-­‐dihydro-­‐[1,3,4]oxadiazole-­‐2-­‐
yl(methyloxyphenyl)-­‐5-­‐methyl-­‐4(4|-­‐substituted	   phenyl	   hydrazono)-­‐pyrazol-­‐3-­‐
ones	  (VII)	  A	  mixture	  of	  VIa	  (0.01	  mol)	  and	  an	  excess	  of	  acetic	  anhydride	  (10	  mL)	  were	  refluxed	  for	  2	  hours.	  	  The	  excess	  acetic	  anhydride	  was	  distilled	  off	  and	  the	  residue	  was	  poured	  on	  to	  crushed	  ice.	  	  The	  solid	  obtained	  was	  filtered,	  washed	  with	  water	  and	  recrystallized	  from	  aqueous	  methanol	  to	  get	  VIIa.	  The	  cyclization	  reaction	  was	  extended	   to	   other	   hydrazones	  VI	   b–j	   and	   in	   each	   case	   the	   respective	   compound	  was	  isolated.	  The	  reaction	  scheme	  is	  given	  in	  Scheme	  2.	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R=H, CH3, OCH3, OC2H5, Cl, Br. 
Scheme	   1.-­‐Synthesis	   of	   {4-­‐[3-­‐Methyl-­‐5-­‐oxo-­‐4-­‐(4|-­‐substituted	   phenyl	   hydrazono)-­‐4,5-­‐dihydro-­‐pyrazol-­‐1-­‐yl]-­‐phenoxy}-­‐acetic	  acid	  hydrazide	  (V).	  	  
	  
 
R = -H, -CH3,  -OCH3, -OC2H5, -Cl, -Br, R1 = -CH3, R2 = -C6H5, p-
CH3C6H4,p-ClC6H4, p-OCH3C6H4,p-NO2C6H4. 
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2.1.3.	  Synthesis	  of	  Mannich	  bases	  containing	  [1,3,4]	  oxadiazole	  and	  pyrazol-­‐3	  
one	  	  nuclei	  (IX)	  
a. 5-­‐methyl-­‐	   4-­‐(4|-­‐substituted	   phenyl	   hydrazono)-­‐2-­‐(5-­‐thioxo-­‐[1,3,4]	  
oxadiazole-­‐2-­‐yl-­‐methyloxyphenyl)-­‐2,4-­‐dihydro-­‐pyrazol-­‐3-­‐one	  (VIII)	  	  A	  mixture	  of	  V	  (19.9	  g,	  0.1	  mol),	  KOH	  (5.5	  g,	  0.1	  mol),	  ethanol	  (100	  mL)	  and	  carbon	  disulphide	  (6.02	  mL,	  0.1	  mol)	  was	  refluxed	  in	  a	  water	  bath	  till	  the	  evolution	  of	  hydrogen	  sulphide	  is	  ceased.	  	  The	  excess	  of	  alcohol	  was	  removed	  by	  distillation.	  	  The	  reaction	  mixture	  was	  cooled	  to	  room	  temperature,	  poured	  into	  ice	  cold	  water	  and	   neutralized	   with	   dilute	   hydrochloric	   acid.	   The	   precipitate	   so	   formed	   was	  filtered,	  washed	  with	  water,	  dried	  and	  recrystallized	  from	  ethanol-­‐dioxane	  mixture	  (1:1)	  to	  give	  VIII.	  	  
b. 5-­‐methyl-­‐4-­‐(4|-­‐substituted	   phenyl	   hydrazono)-­‐2-­‐[5-­‐thioxo-­‐4-­‐
[alkyl/phenyl/heterocyclic	  amino	  methyl]-­‐4,5-­‐dihydro-­‐[1,3,4]	  oxadiazol-­‐
2-­‐yl-­‐methyl]-­‐2,4-­‐dihydro-­‐pyrazol-­‐3-­‐ones	  	  (IX)	  A	  mixture	   of	  VIII	   (0.01	  mol)	   in	   ethanol	   and	  dioxane	   (20	  mL)	  was	   treated	  with	   formaldehyde	  (40%,	  1.5	  mL).	   	  Appropriate	  amine	  (0.01	  mol)	   in	  ethanol	   (10	  mL)	  was	  added	   to	   the	   reaction	  mixture	  and	   stirred	  over	  night.	   	  The	  precipitated	  Mannich	   base	   was	   filtered,	   dried	   and	   recrystallized	   from	   ethanol-­‐DMF	   mixture	  (1:1).	  The	  reaction	  sequence	  is	  outlined	  in	  Scheme	  3.	  	  
	  
	  NHR1R2	   =	   morpholinyl,	   piperazinyl,	   N-­‐methylpiprazinyl;	   R1	   =	   -­‐H,	   R2	   =	   p-­‐Tolyl,	   p-­‐anisyl,	   p-­‐fluorophenyl,	  p-­‐chlorophenyl,	  p-­‐bromophenyl,	  p-­‐nitrophenyl;	  R1	  =	  R2	  =	  ethyl	  or	  phenyl.	  	  
	  
Scheme	  3.Synthesis	  of	  Mannich	  bases	  containing	  [1,3,4]	  oxadiazole	  and	  pyrazol-­‐3-­‐one	  	  moiety.	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2.2.	  Antimicrobial	  activity	  
a.	  Antibacterial	  activity	  
The antibacterial activity of synthesized compounds (250 µg/mL in DMSO) was 
preliminarily studied by disc diffusion method. The procedure followed for the disc 
diffusion method is given below. 
A suspension of Staphylococcus aureus was added to sterile nutrient agar at 
45oC.  The mixture was transferred into sterile petri-dishes to a depth of 3 mm and 
allowed to solidify.  Sterile discs of 5 mm in diameter (made of Whatmann Filter 
paper)were immersed in solutions of synthesized compounds. Sterile discs immersed in 
DMSO were used as control. Both chemical-treated and DMSO-treated discs were laid 
down onto bacteria mixed agar plates. The plates were allowed to stand for 1 hour at 
room temperature followed by incubation at 37oC for 24 hours and observed for 
antibacterial activity. The diameter of the zone of inhibition was measured in each plate. 
The average zone of inhibition was calculated. A similar procedure was adopted for the 
antibacterial activity studies against other organisms. 
b.	  Antifungal	  activity	  The	  procedure	  described	  above	  was	  followed	  for	  antifungal	  activity	  against	  
Aspergillus	   niger	  NCCS	   1196	   and	   Candida	   albicans.	   Compounds	   were	   treated	   at	  several	  different	  concentrations	  using	  DMSO	  as	  a	  solvent.	  	  	  
c.	  Determination	  of	  Minimum	  Inhibitor	  Concentration	  The	  procedure	  followed	  to	  find	  out	  MIC	  by	  Broth	  Dilution	  Method	  is	  given	  below.	  Standardized	   inoculum	   (matched	   to	   McFarland	   BaSO4	   standard)	   of	  suspension	  of	  organisms	  was	  prepared.	  	  A	  series	  of	  glass	  tubes	  containing	  different	  concentrations	  of	  test	  compounds	  dissolved	  in	  DMSO	  and	  spiller	  in	  nutrient	  broth	  were	  incubated	  with	  one	  drop	  of	  inoculum	  and	  shaken	  gently	  to	  mix	  the	  contents.	  	  Two	  growth	  control	  tubes	  were	  also	  prepared	  by	  mixing	  0.1	  mL	  of	  control	  and	  0.9	  mL	  of	  sterile	  saline	  and	  its	  optical	  density	  was	  determined.	  	  The	  control	  contained	  1	  ×	  10-­‐5	  colony	  forming	  units	  /mL	  which	  is	  equivalent	  to	  20	  colonies.	  Tubes	  were	  incubated	  for	  24	  hours	  at	  37oC	  in	  air.	  	  The	  turbidity	  developed	  in	   each	   tube	   was	   recorded	   by	   UV-­‐Visible	   spectrophotometer.	   	   The	   turbidity	  produced	  by	  the	  broth	  (without	  inoculum)	  was	  considered	  as	  100	  %	  transparency.	  	  The	  minimum	   inhibitory	   concentration	   (MIC)	  was	   noted	   as	   the	   concentration	   of	  the	   test	   sample	   which	   completely	   inhibits	   the	   growth	   of	   the	   microorganism	   i.e.	  100	  %	  transparency.	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3.	  RESULTS	  AND	  DISCUSSION	  
3.1.	  Characterization	  of	  synthesized	  compounds	  
a.	   Elemental	   analysis	   details	   of	   compounds	   V	   (-­‐R,	   M.P.,	   Yield,	   Molecular	   formula,	  
Element:	  Found	  %,	  (Calc	  %	  ))	  
Va:	   H,	   152	   oC,	   65	   %,	   C18H22N6O3,	   C:58.37(58.25),	   H:5.94(5.86),	   N:22.70(22.65),	  O:12.97(12.85).	  
Vb:	   CH3,	   153	   oC,	   60	   %,	   C19H24N6O3,	   C:59.37(59.26),	   H:6.25	   (6.17),	   N:21.87(21.76),	  O:12.23(12.14).	  
Vc:	  OCH3,	  156	  oC,	  75%,	  C19H24N6O3,	  C:57.00(55.85),	  H:6.00	  (5.68),	  N:21.00	  (19.85),	  O:16.00	  (15.85).	  
Vd:	   OC2H5,	   168	   oC,	   80	   %,	   C20H26N6O4,	   C:57.97(57.85),	   H:6.28(6.18),	   N:20.28(20.20),	  O:15.45(15.35).	  
Ve:	   Cl,	   174	   oC,	   75	   %,	   C18H21N6O3Cl,	   C:53.39(53.29),	   H:5.19(5.10),	   N:20.76(20.66),	  O:11.86(11.76),	  Cl:8.77(8.66).	  
Vf:	   Br,	   169	   oC,	   65	   %,	   C18H21N6O3Br,	   C:48.11(47.98),	   H:4.71(4.60),	   N:18.17(18.07),	  O:10.89(10.78),	  Br:17.69(17.58).	  
b.	  IR	  (KBr)	  Spectral	  data	  (νmax	  in	  cm-­‐1)	  
Va:	  3445,	  3425	  (NH2),	  3305	  (NH),	  1665	  (C=O),	  1620	  (C=N).	  	  
Vb:	  3400,	  3420	  (NH2),	  3285	  (NH),	  1665	  (C=O),	  1610	  (C=N).	  	  
Vc:	  3425,	  3405	  (NH2),	  3200	  (NH),	  1615	  (C=N),	  1555	  (C=O).	  
Vd:	  3435,	  3415	  (NH2),	  3300	  (NH),	  1615	  (C=N),	  1660	  (C=O).	  
Ve:	  3420,	  3400	  (NH2),	  3275	  (NH),	  1645	  (C=O),	  1610	  (C=N).	  	  
Vf:	  3444,	  3424	  (NH2),	  3290	  (NH),	  1650	  (C=O),	  1605	  (C=N).	  	  
c.	  1H	  NMR	  (DMSO	  –	  d6)	  Spectral	  data	  (δ	  in	  ppm)	  
Va:	  1.2	  (s,	  3H,	  CH3),	  2.1	  (s,	  2H,	  NH2),	  3.85	  (s,	  2H,	  O-­‐CH2-­‐CO)	  6.8	  (s,	  1H,	  Ar-­‐NH)	  7.1-­‐7.3	  (m,	  5H,	  C6H5	  ),	  7.4	  (d,	  2H,	  C6H4),	  7.7(d,	  2H,C6H4),	  8.4	  (s,1H,NH)	  
Vb:	  0.9	  (s,	  3H,	  CH3),	  1.16	  (s,	  3H,	  CH3),	  2.06	  (s,	  2H,	  NH2),	  3.80(s,	  2H,	  O-­‐CH2-­‐CO)	  6.8(s,1H,Ar-­‐NH)	  7.1-­‐7.3	  (m,	  4H,	  C6H4),7.4	  (d,	  2H,	  C6H4),	  7.7(d,	  2H,C6H4),	  8.36	  (s,	  1H,	  N,	  CONH)	  
Vc:	  1.12	  (s,	  3H,	  CH3),	  2.02	  (s,	  2H,	  NH2),	  3.24	  (s,	  3H,	  OCH3),	  	  	  3.76	  (s,	  2H,	  O-­‐CH2-­‐CO),	  6.8	  (s,	  1H,	  Ar–NH),	  7.1-­‐7.3	  (m,	  4H,	  C6H4),	  	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  8.32	  (s,	  1H,	  NH)	  
Vd:	  0.9	  (s,	  3H,	  CH3),	  1.11	  (t,	  3H,	  CH3),	  2.06	  (s,	  2H,	  NH2),	  3.14	  (q,	  2H,	  O–CH2),	  	  	  3.8	  (s,	  2H,	  O-­‐CH2-­‐CO),	  6.8	   (s,	  H,	  Ar–NH),	  7.1-­‐7.3	   (m,	  4H,	  C6H4),	   7.4	   (d,	   2H,C6H4),	   7.7(d,2H,C6H4),	   	   	   8.36	  (s,1H,NH)	  
Ve:	  1.08	  (s,	  3H,	  CH3),	  2.08	  (s,	  2H,	  NH2),	  3.82	  (s,	  2H,	  O-­‐CH2-­‐CO)	  6.8	  (s,	  1H,	  Ar–NH),	  7.1-­‐7.3	  (m,	  4H,	  C6H4),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  8.38	  (s,	  1H,	  NH)	  
Vf:	  1.04	  (s,	  3H,	  CH3),	  2.04	  (s,	  2H,	  NH2),	  3.78	  (s,	  2H,	  O-­‐CH2-­‐CO),	  	  6.8	  (s,	  1H	  Ar–NH),	  7.1-­‐7.3	  (m,	  4H,	  C6H4),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  8.34	  (s,	  1H,	  NH)	  
d.	   Elemental	   analysis	   details	   of	   compounds	   VI	   (-­‐R,	   -­‐R1,	   -­‐R2,	   M.P.,	   Yield,	   Molecular	  
formula)	  
VIa:	   -­‐H,	   -­‐H,	   -­‐C6H5,240	  oC,	   75	  %,	   C26H28N6O3,	  C:66.10(65.95),	  H:5.93(5.83),	  N:17.93(17.80),	  O:10.16(10.02).	  
VIb:	   -­‐CH3,	   -­‐CH3,	   -­‐C6H5,	   245	   oC,	   77	   %,	   C27H30N6O3,	   C:66.66(66.50),	   H:6.17(6.05),	  N:17.28(17.12),	  O:9.87(9.72).	  
VIc:	  OCH3,	  CH3,	  C6H5,	  35	  oC,	  72	  %,	  C27H30N6O4,	  C:64.54(64.42),	  H:5.97(5.83),	  N:16.73(16.58),	  O:12.74(12.62).	  
VId:	   OC2H5,	   CH3,	   C6H5,	   250	   oC,	   73	   %,	   C28H32N6O4,	   C:65.11(64.95),	   H:6.20(6.05),	  N:16.27(16.12),	  O:12.40(12.22).	  
VIe:	  Cl,	   CH3,	  C6H5,	   230	  oC,	  75,	  C26H27N6O3Cl,	  C:61.59(61.42),	  H:5.33(5.23),	  N:16.58(16.46),	  O:9.47(9.33),	  Cl:7.00(6.86).	  
VIf:	   Br,	   CH3,	   C6H5,	   255	   oC,	   78	   %,	   C27H27N6O3Br,	   C:56.63(56.52),	   H:4.90(4.78),	  N:15.24(15.07),	  O:8.71(8.58),	  Br:14.50(14.37).	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VIg:	   H,	   CH3,	   CH3C6H4,	   260	   oC,	   72	   %,	   C27H30N6O3,	   C:66.64(66.48),	   H:6.17(6.05),	  N:17.20(17.07),	  O:9.87(9.70).	  
VIh:	   H,	   CH3,	   ClC6H4,	   265	   oC,	   76	   %,	   C26H27N6O3Cl,	   VIh:	   C:61.59(61.45),	   H:5.33(5.19),	  N:16.58(16.45),	  O:9.47(9.32),	  Cl:7.00(6.85).	  
VIi:	   H,	   CH3,	   OCH3C6H4,	   270	   oC,	   70	   %,	   C27H30N6O4.,C:64.54(64.42),	   H:5.97(5.81),	  N:16.73(16.59),	  O:12.74(12.60).	  
VIj:	   H,	   CH3,	   NO2C6H4,	   272	   oC,	   72	   %,	   C26H27N7O5,	   C:60.34(60.20),	   H:5.22(5.07),	  N:18.95(18.82),	  O:15.47(15.30).	  
e.	  IR	  (KBr)	  Spectral	  data	  (νmax	  in	  cm-­‐1)	  
VIa:	  3185	  (NH),	  1665	  (C=O),	  1600	  (C=N)	  
VIb:	  3175	  (NH),	  1670	  (C=O),	  1602	  (C=N)	  
VIc:	  3200	  (NH),	  1665	  (C=O),	  1605	  (C=N)	  
VId:	  3190	  (NH),	  1670	  (C=O),	  1604	  (C=N)	  
VIe:	  3210	  (NH),	  1650	  (C=O),	  1605	  (C=N)	  
VIf:	  3215	  (NH),	  1660	  (C=O),	  1602	  (C=N)	  
VIg:	  3195	  (NH),	  1670	  (C=O),	  1605	  (C=N)	  
VIh:	  3190	  (NH),	  1675	  (C=O),	  1604	  (C=N)	  
VIi:	  3205	  (NH),	  1660	  (C=O),	  1605	  (C=N)	  
VIj:	  3180	  (NH),	  1660	  (C=O),	  1604	  (C=N)	  
f.	  1H	  NMR	  (DMSO-­‐d6)	  Spectral	  data	  (δ	  in	  ppm)	  
VIa:	  1.52	  (s,	  3H,	  CH3),	  2.35	  (s,	  3H,	  N=C-­‐CH3),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.0	  (s,	  2H,	  O-­‐CH2-­‐CO),	  7.1	  –7.3	  (m,	  10H,	  Ar–H),	  7.4	  (d,	  2H,	  C6H4),	  7.58	  (d,	  2H,	  Ar-­‐H),	  	  7.7	  (d,	  2H,	  C6H4),	  10.92	  (s,	  H,	  NH)	  
VIg:	  1.50	  (s,3H,	  CH3),	  2.26	  (s,	  3H,	  CH3),	  2.33	  (s,	  3H,	  N=C-­‐CH3),	  6.8	  (s,	  H,	  	  Ar-­‐NH),	  7.1-­‐7.3(m,	  9H,	  Ar-­‐H),	  7.23	  (s,	  2H,	  O-­‐CH2-­‐CO),	  	  7.4	  (d,	  2H,C6H4),	  7.7	  (d,	  2H,	  Ar,C6H4),	  10.90	  (s,	  H,	  NH),	  
VIh:	  1.58	  (s,	  3H,	  CH3),	  2.39	  (s,	  3H,	  N=C-­‐CH3),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.27	  (s,	  2H,	  O-­‐CH2-­‐CO),	  	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  10.94	  (s,	  H,	  NH)	  
VIi:	  1.53	  (s,	  3H,	  CH3),	  2.37	  (s,	  3H,	  N=C-­‐CH3),	  6.8	  (s,	  H,	  Ar-­‐NH),	  	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.26	  (s,	  2H,	  O-­‐CH2-­‐CO),	  	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  10.93	  (s,	  H,	  NH)	  
VIj:	  1.48	  (s,	  3H,	  CH3),	  2.30	  (s,	  3H,	  N=C-­‐CH3),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.20	  (s,	  2H,	  O-­‐CH2-­‐CO),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  10.89	  (s,	  H,	  NH)	  
g.	   Elemental	   analysis	   data	   of	   compounds	   VII	   (-­‐R,	   -­‐R1=CH3,	   -­‐R2,	  M.P.,	   Yield,	  Molecular	  
formula,	  Element:	  Found	  %,	  (Calc	  %	  ))	  
VIIa:	   H,	   4|-­‐C6H5,	   240	  oC,	   75	   %,	   C28H30N6O4,	  C:65.36(65.23),	   H:5.83(5.70),	   N:16.34(16.21),	  O:12.45(12.30).	  
VIIb:	  CH3,	  4|-­‐C6H5,	  245	  oC,	  77	  %,	  C29H32N6O4,	  C:65.90(65.72),	  H:6.06(5.92),	  N:15.90(15.75),	  O:12.12(12.00).	  
VIIc:	  OCH3,	  4|-­‐C6H5,	  235	  oC,	  72	  %,	  C29H32N6O4,	  C:63.91(63.76),	  H:5.88(5.74),	  N:15.44(15.30),	  O:14.70(14.56).\	  
VIId:	   OC2H5,	   4|-­‐C6H5,	   250	   oC,	   73	   %,	   C30H34N6O5,	   C:64.51(64.37),	   H:6.09(5.94),	  N:15.05(14.92),	  O:14.33(14.18).	  
VIIe:	  Cl,	  4|-­‐C6H5,	  230	  oC,	  75	  %,	  C28H29N6O4Cl,	  C:61.25(61.10),	  H:5.28(5.12),	  N:15.31(15.19),	  O:11.66(11.44),	  Cl:6.47(6.33).	  
VIIf:	  Br,	  4|-­‐C6H5,	  255	  oC,	  78	  %,	  C28H29N6O4Br,	  C:56.67(56.50),	  H:4.89(4.66),	  N:14.16(14.02),	  O:10.79(10.52),	  Br:13.47(13.30).	  
VIIg:	  H,	  4|-­‐CH3C6H4,	  260	  oC,	  72	  %,	  C29H32N6O4,	  C:65.90(65.72),	  H:6.06(5.87),	  N:15.90(15.78),	  O:12.12(11.95).	  
VIIh:	   H,	   4|-­‐ClC6H4,	   265	   oC,	   76	   %,	   C28H29N6O4Cl,	   C:61.36(61.21),	   H:5.11(5.00),	  N:15.34(15.20),	  O:11.68(11.47),	  Cl:6.17(6.02).	  
VIIi:	   H,	   4|-­‐OCH3C6H4,	   270	   oC,	   70	   %,	   C27H30N6O4,	   C:64.34(64.17),	   H:5.97(5.78),	  N:16.73(16.58),	  O:12.74(12.60).	  
VIIj:	  H,	  4|-­‐NOC6H4,	  272	  oC,	  72	  %,	  C26H27N6O5,	  C:60.34(60.15),	  H:5.22(5.08),	  N:18.95(18.80),	  O:15.74(15.62).	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h.	  IR	  (KBr)	  Spectral	  data	  (νmax	  in	  cm-­‐1)	  
VIIa:	  3206	  (NH),	  1685	  (C=O),	  1620	  (C=N)	  
VIIb:	  3195	  (NH),	  1690	  (C=O),	  1622	  (C=N)	  
VIIc:	  3230	  (NH),	  1685	  (C=O),1625	  (C=N)	  
VIId:	  3215	  (NH),	  1695	  (C=O),	  1624	  (C=N)	  
VIIe:	  3230	  (NH),	  1675	  (C=O),	  1630	  (C=N)	  
VIIf:	  3210	  (NH),	  1685	  (C=O),	  1627	  (C=N)	  
VIIg:	  3180	  (NH),	  1695	  (C=O),	  1627	  (C=N)	  
VIIh:	  3195	  (NH),	  1700	  (C=O),	  1629	  (C=N)	  
VIIi:	  3245	  (NH),	  1705	  (C=O),	  1630	  (C=N)	  
VIIj:	  3240	  (NH),	  1685	  (C=O),	  1630	  (C=N)	  
i.	  1H	  NMR	  (DMSO-­‐d6)	  Spectral	  data	  (δ	  in	  ppm)	  
VIIa:	  2.22	  (s,	  3H	  CH3),	  2.40	  (s,	  3H,	  CH3),	  2.46	  (s,	  3H,	  COCH3),	  5.26	  (s,	  2H,	  OCH2),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4(d,	  2H,	  C6H4),	  7.7	  (d,	  2H,C6H4).	  
VIIg:	  2.20	  (s,	  3H	  CH3),	  2.26	  (s,	  3H,	  CH3),	  2.39	  (s,	  3H,	  CH3),	  2.44	  (s,	  3H,	  COCH3),	  5.24	  (s,	  2H,	  OCH2),	  6.8	  (s,	  H,	  Ar	  -­‐	  NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.	  7	  (d,	  2H,	  C6H4).	  
VIIh:	  2.19	  (s,	  3H,	  CH3),	  2.37	  (s,	  3H,	  COCH3),	  2.24	  (s,	  2H,	  CH3),	  4.92	  (s,	  2H,	  OCH2),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4).	  
VIIi:	  2.18	  (s,	  3H	  CH3),	  2.39	  (s,	  3	  H,	  CH3),	  2.43	  (s,	  3H,	  COCH3),	  3.89	  (s,	  3H,	  OCH3),	  5.24	  (s,	  2H,	  OCH2),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4).	  
VIIj:	  2.16	  (s,	  3H	  CH3),	  2.35	  (s,	  3H,	  CH3),	  2.40	  (s,	  3H,	  COCH3),	  5.22	  (s,	  2H,	  OCH2),	  6.8	  (s,	  H,	  Ar	  -­‐	  NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4).	  
j.	  Elemental	  analysis	  data	  of	  compounds	  VIII	  (M.P.,	  Yield,	  Molecular	  formula,	  Element:	  
Found	  %,	  (Calc	  %	  )	  
VIII:	   150	   oC,	   65	   %,	   C19H20N6O3S,	   C:55.33(55.19),	   H:4.85(4.68),	   N:20.38(20.21),	  O:16.50(16.35),	  S:7.76(7.62).	  
k.	  IR	  (KBr)	  Spectral	  data	  (νmax	  in	  cm-­‐1)	  
VIII:	  3126	  (oxadiazole	  NH),	  3180	  (NH),	  1603	  (C=N),	  1670	  (C=O),	  1134	  (C=S).	  
l.	  1H	  NMR	  (DMSO-­‐d6)	  Spectral	  data	  (δ	  in	  ppm)	  
VIII:	  2.3	  (s,	  3H	  CH3),	  5.45	  (s,	  2H,	  OCH2-­‐),	  6.8	  (s,	  H,	  Ar	  -­‐	  NH),	  7.1–7.3	  (m,	  5H,	  Ar	  -­‐	  H),7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  14.7	  (s,	  H,	  thiol-­‐thione	  tautomeric	  proton	  NH)	  
m.	   Elemental	   analysis	   data	   of	   compounds	   IX	   (R1=H,	   R2,	   M.W.,	   M.P.,	   Yield,	   Molecular	  
formula,	  Element:	  Found	  %,	  (Calc	  %	  )	  
IXa:	   p-­‐tolyl,	   240oC,	   75	   %,	   C27H25N7O3S,	   C:61.48(61.32),	   H:4.47(4.30),	   N:18.59(18.45),	  O:9.10(8.93),	  S:6.07(5.90).	  
IXb:	   p-­‐anisyl,	   245oC,	   77	   %,	   C27H25N7O4S,	   C:59.66(59.48),	   H:4.60(4.56),	   N:18.04(17.85),	  O:11.78(11.62),	  S:5.89(5.69).	  
IXc:	   p-­‐flurophenyl,	   235oC,	   78	   %,	   C26H22N7O3SFl,	   C:58.76(58.65),	   H:4.14(3.98),	  N:18.45(18.33),	  O:9.04(8.86),	  S:6.02(5.80),	  Fl:3.55	  (3.38).	  
IXd:	   p-­‐chlorophenyl,	   250oC,	   73	   %,	   C26H22N7O3SCl,	   C:56.98(56.75),	   H:4.01(3.83),	  N:17.88(17.69),	  O:8.76(8.61),	  S:5.84(5.69),	  Cl:6.48(6.31).	  
IXe:	   p-­‐bromophenyl,	   230oC,	   80	   %,	   C26H23N7O3Br,	   C:52.71(52.58),	   H:3.71(3.59),	  N:16.55(16.38),	  O:8.10(7.92),	  S:5.40(5.23),	  Br:13.49(13.30).	  
IXf:	  p-­‐nitrophenyl,	  255oC,	  83	  %,	  C26H22N8O5S,	  C:55.91(55.74),	  H:3.94(3.78),	  N:20.07(19.87),	  O:14.33(14.21),	  S:5.73(5.57).	  
IXg:	   diethyl,	   260oC,	   72	   %,	   C28H37N8O3S,	   C:59.46(59.28),	   H:6.54(6.39),	   N:19.82(19.70),	  O:8.49(8.32),	  S:5.66(5.44).	  
IXh:	   diphenyl,	   266	  oC,	   70	   %,	   C32H27N7O3S,	   C:65.29(65.18),	   H:4.52(4.62),	   N:17.01(16.63),	  O:8.03(8.14),	  S:5.27(5.44).	  
IXi:	  morpholinyl,	  270oC,	  70	  %,	  C20H18N7O4S,	  C:53.09(52.89),	  H:3.98(3.76),	  N:21.68(21.52),	  O:14.15(13.98),	  S:7.07(6.84).	  
IXj:	   piperazinyl,	  272oC,	  72	  %,	  C22H20N7O3S,	  C:57.14(56.98),	  H:4.32(4.17),	  N:21.21(21.07),	  O:10.38(10.23),	  S:6.92(6.76).	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IXk:	   N-­‐methyl	   piperizinyl,	   267oC,	   68	   %,	   C22H21N7O3S,	   C:57.01	   (56.63),	   H:4.53	   (4.38),	  N:21.16	  (21.02),	  O:10.36	  (10.12),	  S:6.91	  (6.83).	  
n.	  IR	  (KBr)	  Spectral	  data	  (νmax	  in	  cm-­‐1)	  
IXa:	  1608	  (C=N),	  1665	  (C=O),	  1156	  (C=S),	  2939	  (C-­‐HStr),	  3140	  (NH),	  3250	  (Ar	  –	  NH).	  
IXb:	  1620	  (C=N),	  1660	  (C=O),	  1150	  (C=S),	  2925	  (C-­‐HStr),	  3130	  (NH),	  3240	  (Ar	  –	  NH).	  
IXc:	  1610	  (C=N),	  1670	  (C=O),	  1160	  (C=S),	  2945	  (C-­‐HStr),	  3145	  (NH),	  3255	  (Ar	  –	  NH).	  
IXd:	  1608	  (C=N),	  1663	  (C=O),	  1158	  (C=S),	  2940	  (C-­‐HStr),	  3172	  (NH),	  3253	  (Ar	  –	  NH),	  
IXe:	  1609	  (C=N),	  1665	  (C=O),	  1155	  (C=S),	  2943	  (C-­‐HStr),	  3143	  (NH),	  3254	  (Ar	  –	  NH).	  
IXf:	  1605	  (C=N),	  1655	  (C=O),	  1145	  (C=S),	  2930	  (C-­‐HStr),	  3135	  (NH),	  3245	  (Ar	  –	  NH).	  
IXg:	  1590	  (C=N),	  1645	  (C=O),	  1135	  (C=S),	  2925	  (C-­‐HStr),	  3125	  (NH),	  3230	  (Ar	  –	  NH).	  
IXh:	  1593	  (C=N),	  1667	  (C=O),	  1107	  (C=S),	  2940	  (C-­‐HStr),	  3150	  (NH),	  3250	  (Ar	  –	  NH).	  
IXi:	  1610(C=N),	  1675	  (C=O),	  1165	  (C=S),	  2955	  (C-­‐HStr),	  3150	  (NH),	  3265	  (Ar	  –	  NH).	  
IXj:	  1610	  (C=N),	  1670	  (C=O),	  1160	  (C=S),	  2945	  (C-­‐HStr),	  3145	  (NH),	  3260	  (Ar	  –	  NH).	  
IXk:	  1605	  (C=N),	  1655	  (C=O),	  1145	  (C=S),	  2935	  (C-­‐HStr),	  3140	  (NH),	  3255	  (Ar	  –	  NH).	  
o.	  1H	  NMR	  (DMSO-­‐d6)	  Spectral	  data	  (δ	  in	  ppm)	  
IXa:	  2.28	  (s,	  3H,	  CH3),	  	  2.36	  (s,	  3H,	  CH3),	  5.0	  (s,	  2H,	  NCH2),	  	  5.64	  (s,	  2H,	  N-­‐CH2-­‐N),	  	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  11.2	  (s,	  H,	  Ar-­‐NH).	  
IXb:	  2.40	  (s,	  3H,	  CH3),	  3.82	  (s,	  3H,	  CH3),	  5.06	  (s,	  2H,	  N-­‐CH2),	  	  5.62	  (s,	  2H,	  N-­‐CH2-­‐N),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  11.1	  (s,	  H,	  Ar-­‐NH).	  
IXf:	  2.50	  (s,	  3H,	  CH3),	  4.96	  (s,	  2H,	  N-­‐CH2),	  	  	  5.50	  (s,	  2H,	  N-­‐CH2-­‐N),	  	  	  6.8	  (s,	  1H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  7.4	  (d,	  2H,	  C6H4),	  7.7	  (d,	  2H,	  C6H4),	  10.23	  (s,	  1H,	  NH).	  
IXi:	  2.60	  (s,	  3H,	  CH3),	  2.62	  (t,	  4H	  CH2-­‐N-­‐CH2),	  3.70	  (t,	  4H,	  CH2-­‐O-­‐CH2),	  	  4.50	  (s,	  	  2H,	  N-­‐CH2-­‐N),	  5.24	  (s,	  2H,	  N-­‐CH2),	  	  	  5.48	  (s,	  2H,	  N-­‐CH2-­‐N),	  	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.1-­‐7.3	  (m,	  9H,	  Ar-­‐H),	  6.8	  (s,	  H,	  Ar-­‐NH),	  7.4	  (d,2H,C6H4),	  7.7(d,	  2H,	  C6H4),	  10.20	  (s,	  1H,	  NH).	  
IXj:	  2.56	  (t,	  4H	  CH2-­‐N-­‐CH2),	  2.58	  (s,	  3H,	  CH3),	  4.	  45	  (s,	  2H,	  N-­‐CH2-­‐N),	  	  	  	  5.20	  (s,	  2H,	  N–CH2),	  	  5.45	   (s,	   2H,	   N-­‐CH2-­‐N),	   	   4.45	   (s,	   2H,	   N-­‐CH2-­‐N),	   6.8	   (s,	   H,	   Ar-­‐NH),	   7.1-­‐7.3	   (m,9H,	   Ar-­‐H),	  7.4(d,2H,C6H4),	  7.7	  (d,	  2H,C6H4),	  10.19	  (s,	  H,	  NH).	  
3.2.	  Antimicrobial	  activity	  All	   synthesized	   compounds	   were	   subjected	   to	   preliminary	   antibacterial	  screening	   by	   disc	   diffusion	   method	   against	   Staphylococus	   aureus	   NCCS	   2079,	  
Bacillus	   cereus	   NCCS	   2106,	   Escherichia	   coli	   NCCS	   2065	   and	   Pseudomanas	  
aeruginosa	  NCCS	  2200.	  As	  shown	  in	  Table	  1,	  VII	  series	  showed	  moderate	  activity	  against	   tested	   organism.	   In	   this	   series	   chloro,	   bromo	   and	   nitro	   substituted	  compounds	   showed	   more	   activity	   than	   other	   compounds.	   Whereas	   among	   the	  compounds	  of	  IX	   series,	   fluoro,	  chloro,	  bromo,	  nitro,	  morphonilyl,	  piperizynyl,	  N-­‐methylpiperizine	  showed	  more	  activity	  than	  other	  compounds.	  All	   synthesized	   compounds	   were	   subjected	   to	   preliminary	   antifungal	  screening	   by	   disc	   diffusion	   method	   against	   Aspergillus	   niger	   NCCS	   1196	   and	  
Candida	  albicans	  NCCS	  2106.	  Among	  the	  compounds	  of	   VII	   series,	  Chloro,	  bromo	  and	   nitro	   substituted	   compounds	   showed	  more	   activity	   against	  Aspergillus	  niger	  NCCS	   1196	   and	   Candida	   albicans	   NCCS	   2106.	   The	   compounds	   of	   IX	   series	   have	  demonstrated	   good	   antifungal	   activity	   particularly	   fluoro,	   chloro,	   bromo,	   nitro,	  morphonilyl,	  piperizynyl	  and	  N-­‐methyl	  piperizine	  showed	  good	  antifungal	  activity.	  The	  details	  are	  given	  in	  Table	  1	  and	  2.	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Table	  1.-­‐	  	  Antifungal	  activity	  of	  novel	  compounds	  synthesized.	  	   
Com
pound	  
-­‐R	   -­‐R1	   -­‐R2	  
Zone	  of	  inhibition	  in	  mm	  	  




NCCS	  2106	  VIIa	   H	   CH3	   C6H5	   2.25	  (55)	   1.75(52.5)	  VIIb	   CH3	   CH3	   C6H5	   1.75(45)	   1.25(52.5)	  VIIc	   OCH3	   CH3	   C6H5	   1.5(52.5)	   1.5(52.5)	  VIId	   OC2H5	   CH3	   C6H5	   1.5(47.5)	   1.25(50)	  VIIe	   Cl	   CH3	   C6H5	   1.75(40)	   2(120)	  VIIf	   Br	   CH3	   C6H5	   1.75(40)	   1.75(42.5)	  VIIg	   H	   CH3	   CH6C6H5	   1.25(52.5)	   1.25(50)	  VIIh	   H	   CH3	   ClC6H4	   2(37.5)	   1.75(33.75)	  VIIi	   H	   CH3	   OCH3C6H4	   1.5(195)	   1.5(>50)	  VIIj	   H	   CH3	   NO2C6H4	   1.75(41.25)	   1.75(41.25)	  IXa	   H	   H	   p-­‐tolyl	   2.5(45)	   2.25(45)	  IXb	   H	   H	   p-­‐anisyl	   2.25(47.5)	   2(45)	  IXc	   H	   H	   p-­‐fluoro	  phenyl	   3.5(35)	   3(37.5)	  IXd	   H	   H	   p-­‐chloro	  phenyl	   3.25(37.5)	   3.5(36.25)	  IXe	   H	   H	   p-­‐bromo	  phenyl	   3.25(37.5)	   3(37.5)	  IXf	   H	   H	   p-­‐nitro	  phenyl	   3.75(32.5)	   3.25(36.25)	  IXg	   H	   H	   diethyl	  	   2(47.5)	   1.75(47.5)	  IXh	   H	   H	   di	  phenyl	   2(47.5)	   2(47.5)	  IXi	   H	   H	   morphonilyl	   3.5(35)	   3.25(35)	  IXj	   H	   H	   Piperizyinyl	   3.25(37.5)	   3(35)	  IXk	   H	   H	   N-­‐methyl	  piperizine	   3.25(35)	   3.25(32.5)	  
 
Table	  2.-­‐	  	  Antibacterial	  activity	  of	  novel	  compounds	  synthesized.	  
Com
pound	  
Zone	  of	  inhibition	  in	  mm	  	  










NCCS	  2200	  VIIa	   1.5(50)	   1.25(52.5)	   1.25(52.5)	   1.75(45)	  VIIb	   1.5(50)	   1.25(52.5)	   1(55)	   1.5(50)	  VIIc	   1(50)	   1.25(50)	   1(55)	   1.25(52.5)	  VIId	   2(42.5)	   1.5(47.5)	   1(50)	   1.75(47.5)	  VIIe	   2(31.25)	   2.25(35)	   1.5(47.5)	   2(32.5)	  VIIf	   1.75(35)	   2(35)	   1.5(45)	   1.25(47.5)	  VIIg	   1(55)	   1.25(55)	   1(60)	   1.25(60)	  VIIh	   2(31.25)	   2(36.25)	   1.5(40)	   1.75(32.5)	  VIIi	   1(50)	   1.5(47.5)	   1.5(45)	   1.25(50)	  VIIj	   1.75(33.75)	   2(35)	   1.5(38.75)	   1.75(41.25)	  IXa	   1.5(52.5)	   1.75(57.5)	   1.25(57.5)	   1.5(60)	  IXb	   1.75(50)	   1.5(52.5)	   1.5(55)	   1.25(57.5)	  IXc	   2.5(36.25)	   2.75(38.75)	   2.25(38.75)	   2.5(38.75)	  IXd	   3(35)	   2.5(38.75)	   2.25(38.75)	   2.75(36.25)	  IXe	   2.5(37.5)	   2.75(38.75)	   2(40)	   2.25(37.5)	  IXf	   2.75(36.25)	   2.5(38.75)	   2.5(35)	   2.5(35)	  IXg	   1.75(50)	   2(52.5)	   1.5(57.5)	   5(57.5)	  IXh	   1.75(50)	   1.75(50)	   5(60)	   1.5(55)	  IXi	   2.5(37.5)	   3(35)	   2.5(37.5)	   2.75(35)	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Com
pound	  
Zone	  of	  inhibition	  in	  mm	  	  










NCCS	  2200	  IXj	   2.75(32.5)	   2.5(37.5)	   2.25(40)	   2.5(37.5)	  IXk	   2.5(35)	   2.75(35)	   2.25(37.5)	   2.75(35)	  
4.	  CONCLUSSION	  All	   the	   novel	   compounds	   have	   demonstrated	   moderate	   antimicrobial	  activity	  against	  selected	  of	  fungal	  and	  bacterial	  stains.	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